HR. 679In Committee
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Nullifies the FDA's January 2023 mifepristone REMS changes and bars similar future changes to dispensing requirements for the abortion pill
Plain-English overview
What this bill does
Nullifies the FDA's January 2023 mifepristone REMS changes and bars similar future changes to dispensing requirements for the abortion pill
Key points
- Prohibit similar future changes
- Revoke 2023 REMS modifications
Current status
Where it stands
Status
In Committee
Latest action
2025-01-23 — Referred to the House Committee on Energy and Commerce.
Related context
Topics and policy areas
undefinedAbortionDrug safety, medical device, and laboratory regulationDrug therapyHealthPrescription drugs